Pfizer (PFE): What This Company Actually Does

How Pfizer makes money

Pfizer researches and develops patented drugs and vaccines, then sells them at premium prices for as long as patent exclusivity lasts. Most of the money doesn't come from patients directly — it moves through wholesalers to hospitals and pharmacies, and is ultimately paid by government programs like Medicare and private insurers.

The three largest wholesalers (McKesson, Cencora, Cardinal Health) collect more than half of revenue before it ever reaches a patient. Profit flows back into R&D ($10.4B in FY2025) and acquisitions (Metsera, Seagen). Source: 10-K FY2025, p.5, p.101.

Where the revenue comes from

Pfizer reports Biopharma as its single segment, so segment-level operating margins aren't separately disclosed. Source: 10-K FY2025, p.101-102.

Geographically (FY2025): the U.S. is 59.3% ($37.1B), international markets are 40.7% ($25.5B) — with China the largest single international market at 5%, up slightly from 4% in 2024. International's share is actually down from a 2023 peak of 53%, when COVID vaccine sales were still concentrated overseas; it's been normalizing since.

Source: 10-K FY2025, p.6-7, p.36.

Customers and competitors

Pfizer sells almost entirely through three pharmaceutical wholesalers, who together account for 54% of revenue: McKesson (25%), Cencora (16%), and Cardinal Health (13%).

• Merck & Co. — its cancer drug Keytruda competes directly across much of Pfizer's oncology portfolio.
• AbbVie — overlaps with Pfizer's Specialty Care business in immunology and oncology.
• Bristol-Myers Squibb — a co-marketing partner on Eliquis, but a competitor in other cardiovascular and oncology products.

Source: 10-K FY2025, p.101 (wholesaler concentration).

The metric that matters most in this sector

For a patent-driven pharma company, the number that matters most isn't quarterly revenue — it's how much of that revenue depends on patents that are about to expire. Once a patent lapses and generics enter, a drug's sales typically drop by more than half within a year or two.

R&D spending as a share of revenue was 16.7% in FY2025, up from 12.7% five years ago — the pace of reinvestment into the pipeline that has to eventually replace this ~40% of at-risk revenue.

Source: 10-K FY2025, p.7 (patent expiration table), p.101-102 (product revenue), p.51 (R&D spend); 10-K FY2022, p.51 (historical R&D/revenue).

Leadership and ownership

CEO Albert Bourla has led Pfizer since January 2019 and has also chaired the board since January 2020. A veterinarian and pharmacologist by training, he spent over 30 years at Pfizer before becoming CEO, including as COO starting in 2018 — a classic internal-promotion case. There's no founder involvement; Pfizer was founded in 1849 by Charles Pfizer, and that family has been out of management for generations. All directors and executives combined hold under 1% of shares; the largest holders are index funds — Vanguard (8.97%), BlackRock (7.70%), and State Street (5.10%) — none of which are activist investors.

Source: DEF 14A 2026, beneficial ownership and executive officer tables.

Capital returns

Pfizer raised its dividend modestly for three straight years — $1.65/share (2023) to $1.69 (2024) to $1.72 (2025). Buybacks, on the other hand, have been zero for three consecutive years (2023-2025). A $10B repurchase authorization from 2018 still has $3.3B unused, but management has paused buybacks entirely to preserve financial flexibility after funding the $43B Seagen acquisition with debt.

Source: 10-K FY2025, p.75.

How this company could fail

• Patent cliff — Eliquis could face generic competition as early as November 2026 (on the compound patent) or as late as 2028 (under settlement terms). Prevnar, Vyndaqel, Ibrance, and Xtandi all have patents expiring in the same 2026-2029 window, threatening roughly 40% of revenue at once.
• Wholesaler concentration — McKesson, Cencora, and Cardinal Health together account for 54% of revenue, structurally limiting Pfizer's price-negotiation leverage with its own distribution channel.
• Government price controls (the IRA) — under the U.S. Inflation Reduction Act, the government now has authority to directly negotiate Medicare drug prices, and larger-revenue products are more likely to be selected for negotiation.

Source: 10-K FY2025, p.7 (patent expiration table), p.16-26 (Item 1A Risk Factors), p.101 (wholesaler concentration).

Five-year financials

Operating income = revenue minus cost of sales, SG&A, R&D, acquired-IPR&D, amortization of intangibles, and restructuring (derived by exclusion of other income/expense). FCF = operating cash flow minus capex. Total debt = short-term borrowings (including current portion of long-term debt) plus long-term debt. Source: 10-K FY2025, p.51, p.55, p.59-60; 10-K FY2022, p.46; 10-K FY2024, p.56.

What we still don't know

• When Metsera, the obesity-drug company acquired in November 2025, will start contributing meaningful revenue isn't disclosed here — the Q1 FY2026 earnings call would need to be checked.
• Where Comirnaty and Paxlovid (COVID vaccine and treatment) revenue, in decline since 2023, will eventually bottom out isn't yet clear from these filings.
• The final outcome of Eliquis patent litigation — including whether generics could enter as early as November 2026 — remains an open legal question not resolved in this data.